Zimvie (ZIMV) | Financial Analysis & Statements
Zimvie Inc. Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
112.0M
Gross Profit
74.0M
66.12%
Operating Income
3.7M
3.27%
Net Income
-1.5M
-1.31%
EPS (Diluted)
$-0.05
Balance Sheet Metrics
Total Assets
745.8M
Total Liabilities
350.7M
Shareholders Equity
395.1M
Debt to Equity
0.89
Cash Flow Metrics
Operating Cash Flow
-17.1M
Free Cash Flow
-15.4M
Revenue & Profitability Trend
Quarter Income Flow
Mar 31, 2025
Annual Income Flow
2024
Zimvie Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 449.7M | 457.4M | 463.3M | 472.3M | 912.4M |
| Cost of Goods Sold | 162.3M | 167.0M | 169.3M | 176.0M | 312.9M |
| Gross Profit | 287.4M | 290.4M | 293.9M | 296.3M | 599.5M |
| Gross Margin % | 63.9% | 63.5% | 63.4% | 62.7% | 65.7% |
| Operating Expenses | |||||
| Research & Development | 26.9M | 26.2M | 31.1M | 27.3M | 49.2M |
| Selling, General & Administrative | 238.6M | 249.0M | 253.2M | 207.6M | 533.5M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 265.5M | 275.1M | 284.3M | 234.9M | 582.8M |
| Operating Income | -2.1M | -11.3M | -17.3M | 33.2M | -68.8M |
| Operating Margin % | -0.5% | -2.5% | -3.7% | 7.0% | -7.5% |
| Non-Operating Items | |||||
| Interest Income | 7.0M | - | - | - | - |
| Interest Expense | 18.9M | 20.2M | 10.9M | 405.0K | 302.0K |
| Other Non-Operating Income | -9.7M | -19.4M | -26.3M | -12.2M | -152.3M |
| Pre-tax Income | -23.6M | -50.8M | -54.5M | 20.6M | -221.3M |
| Income Tax | 10.2M | 5.2M | -7.6M | 4.2M | -42.3M |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 20.3% | 0.0% |
| Net Income | -25.8M | -393.3M | -63.9M | -95.3M | -179.0M |
| Net Margin % | -5.7% | -86.0% | -13.8% | -20.2% | -19.6% |
| Key Metrics | |||||
| EBITDA | 48.2M | 110.8M | 108.3M | 162.1M | 67.1M |
| EPS (Basic) | $-0.94 | $-14.87 | $-2.45 | $-3.65 | $-6.86 |
| EPS (Diluted) | $-0.94 | $-14.87 | $-2.45 | $-3.65 | $-6.86 |
| Basic Shares Outstanding | 27400000 | 26454000 | 26100000 | 26100000 | 26100000 |
| Diluted Shares Outstanding | 27400000 | 26454000 | 26100000 | 26100000 | 26100000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Zimvie Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 75.0M | 71.5M | 68.3M | 100.4M | 27.4M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 65.2M | 65.2M | 67.0M | 164.2M | 193.7M |
| Inventory | 75.0M | 79.6M | 77.4M | 246.8M | 283.0M |
| Other Current Assets | 670.0K | 852.0K | 1.2M | 25.4M | 21.9M |
| Total Current Assets | 257.3M | 482.9M | 537.9M | 536.9M | 526.0M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 0 | 0 | 270.0M | 315.1M | 324.3M |
| Goodwill | 607.9M | 638.6M | 658.7M | 1.3B | 1.4B |
| Intangible Assets | 92.7M | 114.4M | 138.7M | 766.2M | 891.0M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 34.1M | 291.8M | 647.0M | 75.7M | 75.1M |
| Total Non-Current Assets | 496.4M | 722.5M | 1.1B | 1.3B | 1.4B |
| Total Assets | 753.7M | 1.2B | 1.6B | 1.8B | 1.9B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 33.0M | 27.8M | 26.5M | 45.0M | 49.7M |
| Short-term Debt | 3.9M | 4.1M | 3.4M | 12.6M | 31.6M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 72.2M | 115.7M | 136.2M | 79.7M | 97.8M |
| Total Current Liabilities | 133.9M | 173.6M | 217.3M | 184.6M | 226.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | 228.7M | 517.9M | 542.2M | 45.3M | 57.6M |
| Deferred Tax Liabilities | 0 | 265.0K | 2.2M | 129.5M | 155.2M |
| Other Non-Current Liabilities | 9.2M | 9.1M | 8.9M | 16.0M | 19.7M |
| Total Non-Current Liabilities | 238.0M | 622.2M | 666.1M | 190.8M | 232.5M |
| Total Liabilities | 372.0M | 795.9M | 883.5M | 375.4M | 458.7M |
| Equity | |||||
| Common Stock | 277.0K | 271.0K | 262.0K | 1.5B | 1.5B |
| Retained Earnings | -466.6M | -440.8M | -47.5M | 0 | - |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 381.7M | 409.5M | 758.6M | 1.5B | 1.5B |
| Key Metrics | |||||
| Total Debt | 232.6M | 521.9M | 545.6M | 57.9M | 89.2M |
| Working Capital | 123.3M | 309.3M | 320.6M | 352.3M | 299.8M |
Balance Sheet Composition
Zimvie Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -25.8M | -393.3M | -63.9M | -95.3M | -179.0M |
| Depreciation & Amortization | 34.3M | 121.7M | 122.8M | 129.7M | 134.3M |
| Stock-Based Compensation | 16.6M | 27.0M | 30.3M | 7.3M | 5.9M |
| Working Capital Changes | 8.1M | 11.0M | 8.1M | 45.3M | 5.5M |
| Operating Cash Flow | 33.9M | -247.5M | 28.0M | 65.0M | -56.0M |
| Investing Activities | |||||
| Capital Expenditures | -6.7M | -12.5M | -26.5M | -56.6M | -38.3M |
| Acquisitions | 290.9M | - | 0 | 0 | -8.4M |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | 282.3M | -15.2M | -28.7M | -60.3M | -49.5M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | 0 | 0 | -540.6M | 0 | 0 |
| Debt Issuance | 0 | 4.8M | 595.0M | 0 | 0 |
| Debt Repayment | -290.0M | -29.3M | -58.5M | -16.9M | -668.0K |
| Financing Cash Flow | -296.5M | -27.9M | -2.4M | 72.3M | -46.5M |
| Free Cash Flow | 7.5M | 24.7M | -1.9M | 7.6M | 47.7M |
| Net Change in Cash | 19.7M | -290.6M | -3.0M | 77.0M | -152.0M |
Cash Flow Trend
Zimvie Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-20.20
Forward P/E
28.77
Price to Book
1.30
Price to Sales
1.21
PEG Ratio
3.03
Profitability Ratios
Profit Margin
-4.39%
Operating Margin
3.33%
Return on Equity
-4.76%
Return on Assets
0.51%
Financial Health
Current Ratio
2.37
Debt to Equity
56.82
Beta
2.06
Per Share Data
EPS (TTM)
$-0.69
Book Value per Share
$14.64
Revenue per Share
$15.98
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ZIMV | 535.7M | -20.20 | 1.30 | -4.76% | -4.39% | 56.82 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Boston Scientific | 97.6B | 27.49 | 4.02 | 11.84% | 17.29% | 48.92 |
| Procept BioRobotics | 1.4B | -14.09 | 3.86 | -24.89% | -31.02% | 21.45 |
| QuidelOrtho | 765.2M | - | 0.42 | -46.15% | -41.46% | 148.60 |
| Enovis | 1.3B | -1.10 | 0.91 | -58.27% | -52.69% | 92.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.






